- Title
- Stroke units, tissue plasminogen activator, aspirin and neuroprotection: Which stroke intervention could provide the greatest community benefit?
- Creator
- Gilligan, A. K.; Thrift, A. G.; Sturm, Jonathon W.; Dewey, H. M.; Macdonell, R. A. L.; Donnan, G. A.
- Relation
- Cerebrovascular Diseases Vol. 20, no. 4, p. 239-244
- Publisher
- Karger
- Resource Type
- journal article
- Date
- 2005
- Description
- Background: Although a number of acute stroke interventions are of proven efficacy, there is uncertainty about their community benefits. We aimed to assess this within a defined population. Methods: Eligibility for tissue plasminogen activator (tPA), aspirin, stroke unit management and neuroprotection were assessed among incident stroke cases within the community-based North East Melbourne Stroke Incidence Study. Results: Among 306,631 people, there were 645 incident strokes managed in hospital. When eligible patients were extrapolated to the Australian population, for every 1,000 cases, 46 (95% CI 17-69) could have been saved from death or dependency with stroke unit management, 6 (95% CI 1-11) by using aspirin, 11 (95% CI 5-17) or 10 (95% CI 3-16) by using tPA at 3 and 6 h, respectively. Conclusions: Although tPA is the most potent intervention, management in stroke units has the greatest population benefit and should be a priority. Copyright (C) 2005 S. Karger AG, Basel.
- Subject
- stroke, acute; tissue plasminogen activator; community-based stroke; units; acute ischemic-stroke; thrombolytic therapy; experience; care; management; Australia; delays
- Identifier
- uon:287
- Identifier
- http://hdl.handle.net/1959.13/25088
- Identifier
- ISSN:1015-9770
- Language
- eng
- Reviewed
- Hits: 8917
- Visitors: 5044
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|